• First Indian drug maker for respiratory solutions to tap into the foreign market
• To help manage respiratory conditions like asthma and COPD
• Nepal accounts for 100 deaths per 100,000 every year due to respiratory disease

Pune, 24 April 2024: SAVA Healthcare Limited (SHL), a leading player in nasal spray and healthcare segment, has forayed into foreign market with its latest Dry Powder Inhaler (DPI) product to treat respiratory diseases. Labelled as SAVACORT, Nepal’s Humankind Healthcare collaborated with SHL to launch a range of other respiratory solutions in the country. The products are set to hit pharmacy shelves in Nepal, marking a significant expansion for SHL into the global healthcare landscape.

SAVACORT comes with a unique formulation that offers rapid onset of action in conditions like asthma and chronic obstructive pulmonary disease (COPD).

At the launch event, Aniruddha Rajurkar, CEO, SAVA Healthcare Limited, said: “SAVACORT represents a paradigm shift in respiratory care, signifying our commitment to innovation and patient-centric solutions. This launch signifies a timely response to the growing demand for advanced treatment options in Nepal.”

According to the US department of Health and Human Services, the respiratory disease is on the rise with nearly 545 million people currently living with a chronic respiratory condition, globally. Where Nepal alone accounts for more than 100 deaths per 100,000 every year. Designed to address the pressing needs of individuals grappling with respiratory ailments, the SAVACORT DPI boasts of unparalleled efficacy in managing symptoms.

“The introduction of SAVACORT in Nepal marks a milestone in our efforts to enhance respiratory care in the country. We are confident that this collaboration will significantly benefit patients and healthcare professionals and look forward to making a positive impact on the respiratory health of the Nepalese population,” said Kiran Duwadi, Managing Director, Humankind Healthcare Pvt. Ltd., Nepal.

The launch event saw distinguished gathering of over 100 DM & MD Pulmonologists of Nepal, alongside leading chest physicians and the President of the Nepalese Respiratory society. SAVA Healthcare’s decision to expand its reach into Nepal makes it the first Indian drug maker offering respiratory solutions in the foreign market.

About SAVA Healthcare:

SAVA Healthcare Limited, headquartered in India, operates a Health Canada and PIC/s certified manufacturing facility in Gujarat, alongside an advanced R&D centre in Pune. The company is organized into four key sectors: International Business, Contract Research & Manufacturing Services (CRAMS), Companion Animal (CA) Healthcare, and Farm Animal (FA) Healthcare, as well as a specialized division, SAVA Herbals. Its International Business division extends SAVA’s reach globally, distributing both human and veterinary pharmaceuticals across North America, Central America, Asia, Africa, and the CIS countries.

Renowned for its expertise in Nasal Drug Delivery Platforms, SAVA’s CRAMS division has established itself as a reliable partner, catering to a diverse clientele of Indian and international companies. This commitment to quality and innovation positions SAVA Healthcare as a prominent player in the pharmaceutical industry.

For more information:

www.savaglobal.com | www.savavet.com | www.savaherbals.com

SAVA Healthcare to Elevate Respiratory Solutions in Nepal with its Dry Powder Inhaler